

Biographical Sketch of Gerry MELINO



Professor Gerry Melino, MD (Rome), PhD (London), Dr Sci hc (St Petersburg), member Accademia Lincei and also Academia Europaea, works at the University Tor Vergata of Rome in Italy (Professor of Biochemistry & Director of Centre of Excellence “Torvergata Oncoscience Research”).

He has created a major forum for discussion and innovation in the field of cell death in the last 25 years, being the Founder & Editor-in-Chief of the journals “Cell Death Differentiation” (www.nature.com/cdd), “Cell Death Disease” (www.nature.com/cddis) and “Cell Death Discovery” (www.nature.com/cddiscov), impact factor 10.8, 6.4 and 4.4 respectively.

Awards: (2009) Feltrinelli Prize by Accademia Lincei (founded 1603) presented by the President of Italy. (2010) Antonini Prize, Italian Society of Biochemistry. (2011) Morgagni Medal. Morgagnane Lectures 250th Anniversary. University of Padua. (2012) Doctor Science Honorary Degree, Saint Petersburg Institute of Technology. (2013) Chancellor’s Award on Neuroscience. Louisiana State University, USA. (2014) Honorary Professor & Advisory at Shanghai Jiao Tong University, School of Medicine, China. (2015) Senate Medal. Cancer Centre. Hawaii State, USA. (2016) Distinguished Career Award, European University of Cyprus. (2018) Medicine Dean’s Award. Louisiana State University, USA. (2018-22) President, European Cell Death Organization.

His **Training** originated in Italy and in particular Rome, where he obtained his MD (1978, Rome) followed by clinical specialisations in Paediatrics (1981, Rome) and Clinical Oncology (1985, Rome). Following his PhD in 1979-1984 at the University of London in the Chemical Pathology Department, Charing Cross & Westminster Medical School, he worked as Research Fellow, Lecturer and Senior Lecturer (Consultant) until 1987. He returned to Italy in 1988 to the University of Rome as a Lecturer before becoming a full Professor in 1994. Professor Melino has acted as Consultant and Scientific Advisor for several companies and government institutions.

His **Scientific Interests** are focused on Programmed Cell Death, apoptosis, in neural and epidermal models, where his contribution has been fundamental. Originally, he worked on cell death in the skin, i.e. cornification; in particular on its molecular mechanisms, working in vitro and in animal models as well as in human genetic pathologies. He identified the role of transglutaminases (type 1, 2, 3, and 5) and their substrates (SPRs, lorincrin, keratins) at biochemical and genetic levels. While still maintaining an interest in these aspects, his current work is focused on the p53/p63/p73 family. DNA damage elicits repair mechanisms involving the tumour suppressor gene p53 and the two newer members of the same family: p63 and p73. The molecular events driven by DNA damage to elicit the function of p63/p73 and their transcriptional regulation, is investigated in vitro. The molecular mechanisms of apoptosis and their protein stability and degradation is under investigation. Transgenic mice and knockouts for p63/p73 are in progress.

Cites GS: 64777 cites, H-index 111 (WOS: 40691 cites, H-index 91) (Scopus: 43345 cites, H-index 92).

Clinical Discoveries:

- Identified the cause of six Diseases by Mutations of K13 (OMIM #193900), FALDH (OMIM #270200); TG1 (OMIM #242300); TG2 (OMIM #606391); TG5 (OMIM #606391); U2HR (OMIM #146550).
- Identified a New Disease: Unilateral Palmoplantar Verrucaeus Nevous (OMIM #144200).

Selected Papers:

1. Melino G, et al. S-nitrosylation regulates apoptosis. **Nature**. 1997. 388: 432-433.
2. Gong JG, et al. Regulation of the p53 homolog p73 by c-Abl tyrosine kinase in cell death response to cisplatin. **Nature**. 1999. 399: 806-9.
3. Melino G. The Syren’s song (Concept: apoptosis). **Nature**. 2001. 412:23.
4. Rossi M, et al. The E3 ubiquitin ligase ITCH controls the protein stability of p63. **PNAS-USA**. 2006. 103, 34: 12753-58.
5. Levine AJ, et al. The p53 family: guardians of maternal reproduction. **Nature Review Mol Cell Biol**. 2011. 12(4): 259-65.
6. Amelio I, et al. TAp73 opposes tumor angiogenesis by promoting HIF-1 α degradation. **PNAS-USA**. 2015; 112(1):226-31.
7. Viticchiè G, et al. p63 supports aerobic respiration through hexokinase II. **PNAS-USA**. 2015; 112(37):11577-82.
8. Inoue S, et al. Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA Damage independent of TET2. **Cancer Cell**. 2016. 30(2): 337-48.
9. Marini et al. TAp73 contributes to oxidative stress response by regulating protein synthesis. **PNAS-USA**. 2018;115:6219-24
10. Amelio I, et al. p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. **PNAS-USA**. 2018;115(46):E10869-E10878.
11. Amelio, et al. The C terminus of p73 is essential for hippocampal development **PNAS-USA**. 2020; 117(27):15694-15701.
12. Lena, et al. The p63 C-terminus is essential for murine oocyte integrity. **Nature Comms**. 2021; 12,1:383

Curriculum Vitae

NAME **Gerry Gennaro MELINO, MD, PhD, Dr Sci hc**
(Citizenship: Italian)

ADDRESS via delle Egadi 1. 00141 Roma. Italia
cell phone +39-380 320 9966, email: melino@uniroma2.it

PRESENT POSITION

Since 1994. Professor of Biochemistry & Director of the Centre of excellence 'Torvergata Oncoscience Research' (TOR), Faculty of Medicine, University of Rome 'Tor Vergata'. TOR includes 11 full professors, technical and administrative staff.

EDUCATION

1978 M.D. (Rome). Final grade 110/110 cum laude (honours)
1981 Specialisation in Paediatrics (Rome). (Accreditation). Final grade 70/70 cum laude (honours)
1984 Ph.D. (London) in Tumour Immunology. Examiners Profs A Davies and G Janossy, supervisor JR Hobbs
1985 Specialisation in Oncology (Rome). (Accreditation). Final grade 70/70

AWARDS

2009 "Feltrinelli Prize" by the "Accademia dei Lincei" awarded by the President of Italy.
2010 Member, Academia Europaea.
2010 "Antonini Award", Italian Biochemical Society.
2011 Morgagni Medal. Morgagnane Lectures 250th Anniversary. University Padua, Italy
2012 Honorary Degree in Biotechnology, Saint Petersburg Institute of Technology, Russia
2013 Chancellor's Award in Neuroscience. Louisiana State University, USA
2014 Honorary Professor & Advisory at Shanghai Jiao Tong University, School of Medicine, China.
2015 Senate Medal. Cancer Centre. Hawaii State, USA
2016 Distinguished Career Award, European University of Cyprus.
2018 Honorary Citizenship, city of Frasinetto (Italy)
2018 ECDO (European Cell Death Organization) President Elect (2018-20), President (2020-22).
2018 Dean's Award in Medicine & Neuroscience. Louisiana State University, USA
2019 Member, Accademia Lincei.

PREVIOUS APPOINTMENTS

1972 to 1979 Biochemistry Institute of Rome University. Research student. Worked under the supervision of Profs. E. Chiancone and E. Antonini. Experimental work on structure-function relationship of ferritin. Worked with Profs. A. Finazzi-Agro` and S. Stefanini, carrying out experiments on circular dichroism, spectrophotometric kinetics, analytical ultracentrifuge and manometric experiments.

During that time has worked twice in UK (1.9.76 to 15.12.76 and 30.11.77 to 15.1.78) at the Biochemistry Dept., Lancaster University, UK. Visiting research student with Prof. C. Phelps on the interaction between calcium and heparin, using flow dialysis techniques.

1979 to 1986 Chemical Pathology Dept., Charing Cross & Westminster Medical School, University of London. Worked with Prof. J.R. Hobbs on clinical and experimental tumour immunology of paediatric tumours and bone marrow transplantation. In particular on Drug Targeting *in vitro* and on patients, using allogeneic antineuroblastoma antibodies coupled to chlorambucil and daunorubicin. Appointments:

- i 1.11.79 to 1.3.83 Research Fellow and Hon. Senior Registrar.
- ii 1.3.83 to 1.11.85 Lecturer in Clinical Immunology (Hon. Senior Registrar).
- iii 1.11.85 to 31.12.86 Senior Lecturer, Hon. Consultant in Chemical Immunology, Deputy-director of department

1987 to 1994 Research Fellow in Biochemistry (1987-1994), Experimental Medicine & Biochemistry Dept., University of Rome Tor Vergata, Italy. Locum Professor of Biochemistry (1991-1994), Biology Faculty, University of L'Aquila.

1994 to 1998 Full Professor of Biochemistry (1991-1998), Biology Faculty, University of L'Aquila.

2010 Jan to Dec Scientific Director, European Brain Research Institute, Rita Levi-Montalcini Foundation, Rome.

2011 to 2015 Supervisor of the Megagrant at the "Saint Petersburg Institute of Technology", Russia, to establish a molecular pharmacology research team at the Mendeleev Institute.

2012 Jan to Dec Older of the FWO Odysseus grant, Cell Metabolism Laboratory, at the VIB, Ghent, Belgium.

1998 to 2007 Full Professor of Biochemistry (1998-1999) and Molecular Biology (1999-2007), Experimental Medicine & Biochemistry Dept. University of Rome Tor Vergata.

2007 to 2018 Director, Experimental Medicine & Surgery Dept. University of Rome Tor Vergata. The Department includes 19 full professors, 35 associate professors, 57 assistant professors, 62 technical and administrative staff. In addition to the 173 staff members, there are over 100 PhD students, surgeons and doctors in training.

2003/1 to 2020/9 Programme Leader, Medical Research Council (MRC), Toxicology Unit, University of Cambridge, UK (In Leicester till 2017). Head of "Theme 2" on Genes-Environment interactions following toxic insults (5 research groups).

ADMINISTRATIVE & MANAGERIAL EXPERIENCE

1. 25-years, extensive experience at editorial levels (3500 manuscripts submitted yearly).
2. 10-years, experience as Director of a Department in Italy with 173 staff + 100 students. This includes a significant number of surgeons as well as scientists with distinct translational issues.
3. 15-years, responsible for a 5-team Programme at MRC.

ACADEMIC EXPERIENCE

Academic positions in UK:

1. Chemical Immunology at the Charing-Cross & Westminster Medical School, London University, UK: Lecturer (1983-1984); Senior Lecturer (1985-1986).

Academic positions in Italy:

2. Biochemistry, Faculty of Medicine & Surgery, University Rome Tor Vergata: Assistant Professor (Ricercatore Bio/10) (30/07/1984-1994).
3. Biochemistry, Biology Faculty, L'Aquila University: Locum Professor (Incaricato Bio/10) "Biochemical Methods" (1991-1994).
4. Biochemistry, Biology Faculty, L'Aquila University: Full Professor (Professore Straordinario & Professore Ordinario, Bio/10) (1994-1998).
5. Biochemistry, Faculty of Medicine & Surgery, University Rome Tor Vergata: Full Professor (Professore Ordinario Bio/10) (1998-1999) and (2016-present).
6. Molecular Biology, Faculty of Medicine & Surgery, University Rome Tor Vergata: Full Professor (Professore Ordinario Bio/11) (1999-2016).

Visiting & Adjunct:

7. Biochemistry PhD, Adjunct Professor, P & M Curie University of Paris VI (yearly 1994-2003).
8. Visiting Professor: (i) University of Paris (1992-2001). (ii) University of Tucuman, Argentina (April 1997). (iii) Foundation for Promotion of Cancer Research, National Cancer Center Hospital, Tokyo, Japan (Feb. 1999). (iv) University of El Mansura, Egypt (March 1999). (v) Yamagata University, Japan (Feb. March 2003). (vi) Tirana University, Albania (Feb 2005).

PATENTS

2003- WO03/025010A2 "Human delta-N p73 molecules and uses thereof" (EiRx)

2005- US5309883, P021493GB, P021493WO granted 2006 "ITCH inhibitors as Targets for Therapy" (MRC)

- 2010- EP10305617.2; EP2580327B granted 2014; WO2011/154402A1 granted 2014; US2013071370 pending; JP2013529091 pending. "Inhibition of microRNAs for use for preventive and/or attenuating skin ageing and/or for hydrating skin" (Chanel, miR, keratinocytes)
- 2012- EP12306029.5 granted 2015, EP2703498B1, "Inhibition of microRNAs for use for preventive and/or attenuating skin ageing" (Chanel, miR, fibroblasts)
- 2013- Russia N. 2013621492. "Small molecule inhibitors of mdm2 to stabilize p53".

EDITORIAL EXPERIENCE

[all currently active]

1. Founder Editor-in-Chief for "CELL DEATH DIFFERENTIATION" (Nature Publishing Group, London; www.nature.com/cdd), Impact Factor 8.5.
2. Founder Editor for "CELL DEATH & DISEASE" (Nature Publishing Group, London; www.nature.com/cddis. Impact Factor 5.98.
3. Founder Editor, "CELL DEATH DISCOVERY" (Nature Publishing Group, London; www.nature.com/cddiscover).
4. Editorial Board of "ONCOGENE", Nature Publishing Group, London (www.nature.com/onc).
5. Editorial Board of "BIOCHEMICAL JOURNAL", Portland Press, UK
6. Editorial Board of "CELL CYCLE", Landes Bioscience, Editor-in-Chief M Blagosklonny.
7. Editorial Board of "CANCER BIOLOGY & THERAPY" Landes Bioscience, Editor-in-Chief W.El-Deiry.
8. Editorial Board of "MOLECULAR NEUROBIOLOGY", Blackwell, Editor-in-Chief N Bazan.
9. Editorial Board of "AGING", Impact-Aging, Landes Bioscience.
10. Editorial Board of "MOLECULAR ONCOLOGY", [FEBS-press} by Wiley
11. Referee for several scientific journals (e.g. Science, Nature, Nature Reviews, Nature Medicine, EMBO J, MCB, JBC, JID, Cancer Res, J Cell Physiol, J Neurochem, Br J Cancer, Int J Cancer, Exp Cell Res).

CONSULTANT, MANAGING, BIOTECH EXPERIENCE

1. Scientific Advisory Board of Biotech Companies: "EiRx Therapeutics", Ireland, Capgene (Paris), BioUniSA (Salerno), Chanel Parfume Beaute (Paris).
2. Consultant for several groups: Promark Ltd (UK), TotalRes Co. Ltd (UK) Serono Co. (CH), Chanel (F).
3. Scientific Advisory Board for the Government of Ireland (SFI), UK (MRC), Finland (Academy of Science), Belgium (VIB), China (ISBS), Italy (CNR).

SCIENTIFIC INTERESTS & ACHIEVEMENTS

-1- The p53 family in cancer

Gerry has a high reputation and appreciation by the international scientific community for his cancer and cell death work. His current scientific interest stemmed from the biochemistry of nitric oxide and skin cell death, towards the function of the p53 protein family, namely p63 and p73. He cloned and biochemically characterized several isoforms of p63 and p73 and developed innovative ad hoc mouse models, resulting in high-class publications. Indeed, this work has relevant implications both in tumour suppression and programmed cell death and lead to high quality papers. Indeed, Gerry has published over 500 papers in respected journals (including for example 29xPNAS-USA, 4xNature, 34xOncogene, 16xJ Invest Dermatol, 5xGenes Dev, 13xJournal Biological Chemistry, 3xJ Exp Med, 3xNature Reviews, 5xTiBS). The relevance of this scientific work is also evident from the very prestigious conferences he has been invited to attend, including several Nobel Conferences.

-2- Skin Cell Death

For long time, Gerry has collaborated with the largest Italian Dermatology Hospital, IDI-IRCCS, developing biochemical and genetic model of human disease. The death of keratinocytes, also known as cornification or formation of the cornified envelope, involves molecular events that have been investigated in vitro and in animal models as well as in human pathologies. The role of transglutaminases (type 1, 2, 3, and 5) and their substrates (SPRs, loricrin, filaggrin, keratins) have been characterized at the biochemical level and creating specific knockout mice. These mechanisms have been evaluated in skin diseases including lamellar ichthyosis, palmoplantar keratosis, pachionikya congenita, Vowinkel syndrome, Sjogren-Larsson syndrome. His group has identified a new disease, Unilateral Palmoplantar Verrucaeus Nevous (OMIM #144200), and contributed to the understanding of the cause of six other diseases by mutations of K13 (OMIM #193900), FALDH (OMIM #270200); TG1 (OMIM #242300); TG2 (OMIM #606391); TG5 (OMIM #606391); U2HR (OMIM #146550).

-3- Editorial Activity

Gerry contributed to science also by creating 3 distinct scientific journals, all from Springer Nature (previously Nature-Publishing-Group). This is a very unusual way of contributing to the scientific community, and could be the base for a peculiar contribution to the Accademia dei Lincei. At a time when few were venturing in the complexity of

scientific journals, Gerry identified an empty editorial niche and in 1994 created *Cell Death & Differentiation*, the first, and until today -with 25 years history- the best journal in the cell death community with a stable impact factor of 8-9. Subsequently, he created *Cell Death & Disease*, in 2010 (now with an impact factor of 6), and *Cell Death Discovery*, in 2015. The journals receive over 4,000 submission yearly and are expanding beyond the strict "cell Death" community into translational cell biology.

STAFF & FUNDING

The ROME GROUP includes 6 assistants (permanent positions, including 1 Full and 2 Associate professors), 4 post-Docs and 4 PhD students. Attracts about euro 350,000 per year in grants from industry, Health Ministry, EU. The CAMBRIDGE GROUP, entirely core-founded by MRC, includes 5 assistants/post-Docs. *Some Major Grants:* Russian Federation, Leading Scientists "p53 family" 2011-2013. Financed: € 3,800,000.00 Ministry Education and Science of the Russian Federation. MegaGrant n. 11.G34.31.0069
 Research Foundation Flanders, Belgium (FWO)"p73/p63" 2012-2018. Financed: € 7,500,000.00 Contract G.0017.12 Title: The p53 family in Cancer & Inflammation.
 MRC, Toxicology Unit Intramural support "p53/p73 in Toxicology" 2005-2011. Financed: UK £ 2,100,000.00
 MRC, Toxicology Unit Intramural support "p73/p63" 2012-2017. Financed: UK £ 2,300,000.00
 MRC, Toxicology Unit Intramural support "Genes vs Environment, p73/p63" 2018-2023. Financed: UK £ 3,400,000.00
 EU n. LSHB-CT-019067 "Epistem" (Vandenabeele) 2006-2010. Financed: € 1,280,000.0
 EU n. LSHC-CT-2004-503576 "Active p53" (Blandino) 2005-2008. Financed: € 225,000.00
 AIRC IG11955 2011-2014 p73 in cancer metabolism and senescence . 330,000 €
 AIRC IG15653 2015-2017 Dissecting the role of p73 in lung tumorigenesis and cancer progression. 330,000 €
 AIRC 5xmille #9979 2010-17 Development of cancer therapies based on functional proteomics & cancer stem cell. 1,106,498 €
 AIRC IG20473 2018-2022 Role of the TAp73 interactome in lung tumour suppression. 600,000 €
 Fondazione Roma 2015-2017 "p73/p63 in organismal aging and energy metabolism". 400,000€
 Telethon GGP09133 2009-2012 "Function of p63 in normal skin and in ectodermal dysplasia syndromes". 223,000 €
 MAE. Cooperazione Italia-Cina 2018-2020 Famiglia di p53 nel rimodellamento osseo e osteosarcoma. 495.000 €
 Regione Lazio Lazioinnova 2018-2020 RNA non codificanti nel DNA indotto da UVB. 126.757€
 PRIN17 2017BF3PXZ_002 2015-2017 "Mitochondrial dynamics in cancer: HIF1, hedgehog, Rap1". 209.800 €
 Min Sanita'. RC-IDI-2005-2017. Yearly grants between 50,000-220,000 €

STAFF TRAINED

More than 60 students have obtained the PhD or MD under the supervision of Prof. G Melino. The following 25 now have a permanent position in Scientific Institutions: *A Oberst* (Associate Professor, Seattle, USA), *A Stephanou* (Full Professor, European Univ Cyprus), *ES El Sherbini El Said* (pro-Rector, ex-Dean; University El Mansura, Egypt), *V De Laurenzi* (Full Professor, Univ Chieti, I), *E Candi* (Full Professor, Univ Rome 2, I), *MV Catani* (Associate Professor, Univ Rome 2, I), *F Bernassola* (Assistant Professor, Univ Rome 2, I), *S Oddi* (Assistant Professor, Univ. Teramo, I), *P Tucci* (Assistant Professor, Univ. Cosenza, I), *L Bellincampi* (Research Assistant, Univ Rome 2, I), *A Paradisi* (Research Assistant, Univ. Lyon, F), *M Annicchiarico* (Research Associate, IDI-IRCCS, Rome, I), *A Terrinoni* (Associate Professor, Univ Rome 2, I), *A Peschiaroli* (Research Associate, CNR, Rome, I), *L Bongiorno-Borbone* (Research Assistant, Univ Rome, I), *AM Lena* (Research Assistant, Univ Rome, I), *M Ranalli* (Research Assistant, Univ Rome, I), *M Papi* (Research Assistant, Univ Rome, I), *D Barcaroli* (Research Assistant, Univ Chieti, I), *M Rossi* (PI, Max-Planck, Buenos Aires, Argentina), *AE Sayan* (Lecturer, Southampton, UK), *BS Sayan* (Lecturer, Southampton, UK), *M Agostini* (Associate Professor, Univ Roma 2), *A Rufini* (Lecturer, Leicester, UK), *B Rotblat* (PI, Univ Bel Sheva, Israel), *NA Barlev* (Associate Professor, Univ St Petersburg, Russia), *I Amelio* (PI, MRC Leicester).

PUBLICATIONS

GM has over **650 publications** in *Nature* (6x), *PNAS-USA* (29x), *Oncogene* (34x), *Genes Dev* (5x), *Nature Reviews* (3x), *TiBS/TCB* (5x), *J Cell Biol* (1x), *Nature Commun* (3x), *Nature Med* (1x), *Cancer Cell* (2x), *Embo J* (3x), *J Exp Med* (3x), *J Invest Dermatol* (16x), *Cancer Res* (7x), *Cell Death Differ* (73x), *Cell Death Dis* (25x), *Cell Cycle* (30x), *Oncotarget* (22x), *Aging (Albany NY)* (10x), *FEBS Lett* (6x), *Biochem Pharmacol* (7x), *Biochem J* (4x), *Diabetes* (2x), *Hum Mutat* (2x), *Biochem Biophys Res Commun* (44x), *Autophagy* (3x), *Stem Cells* (1x), *Embo Mol Med* (1x), *J Cell Sci* (4x), *Mol Neurobiol* (6x), *Gastroenterology* (1x), *Circulation* (1x), *J Immunol* (4x), *Int J Cancer* (3x), *others*

IMPACT FACTOR, CITATIONS, H-INDEX

Impact factor (cumulative) is 3550 (1079 in last 5 years).

Citations & H-index :

ISI-Clarivate (WOS): 47434 citations, 93 H-index (average of 55.1 citations per paper)
 Scopus: 41836 citations, 91 H-index
 Google Scholar: 65621 citations, 111 H-index

15 Most Cited Papers

6925 citations – Klionsky et al.	Autophagy. 8,4: 445.	(2012)
2639 citations – Kroemer et al.	Cell Death Differ. 16: 3.	(2009)
2004 citations – Galluzzi et al.	Cell Death Differ. 19: 107.	(2012)
1387 citations – Candi et al.	Nature Review MCB. 6: 328.	(2005)
1029 citations – Gong et al.	Nature. 399: 806.	(1999)
731 citations – Kroemer et al.	Cell Death Differ. 12: 1463.	(2005)
616 citations – Levrero et al.	J Cell Sci. 113: 1661.	(2000)
581 citations – Melino et al.	Nature Review Cancer. 2: 605.	(2002)
573 citations – Galluzzi et al.	Cell Death Differ. 16: 1093.	(2009)
545 citations – Galluzzi et al.	Cell Death Differ. 22: 58.	(2015)
474 citations – De Laurenzi et al.	J Exp Med. 188: 1763.	(1998)
470 citations – Melino et al.	Nature. 388: 432.	(1997)
412 citations – Bernassola et al.	Cancer Cell. 14,1: 10-21.	(2008)
403 citations – Lena et al.	Cell Death Differ. 15,7: 1187.	(2008)
400 citations – Melino et al.	JBC. 279,9: 8076.	(2004)

MAJOR CLINICAL FINDINGS

1. Mutations K13 cause White Spongioid Nevus of Cannon (OMIM [#193900](#))
2. Mutations FALDH, long chain fatty acids, cause Sjogren-Larsson Syndrome (OMIM [#270200](#))
3. Mutations TG1 cause Lamellar Ichthyosis (OMIM [#242300](#))
4. Mutations TG2 cause MODY type 7 (OMIM [#606391](#))
5. Mutations TG5 cause Acral Exfoliative Syndrome (OMIM [#606391](#))
6. Mutations U2HR cause Marie Unna hypothyrosis (alopecia) (OMIM [#146550](#))
7. New Disease: Nevus Verrucosus Palmoplantare Unilaterale (OMIM [#144200](#))

MAJOR RESEARCH FINDINGS

1. p73/p63 degradation mechanism (ITCH E3 Ubiquitin Ligase)
2. Developed ITCH inhibitors.
3. p63/p73 mechanisms of cell death.
4. p63/p73 transcription targets.
5. Developed p63/p73 transgenic mice.
6. Nitric Oxide regulates cell death.
7. Role of Transglutaminases and their substrates in skin development.

MEETINGS

[as invited speaker, chair or organizer]

1. 1st Intensive course on basic immunology, EMBO. 10-29 September 1979, Pavia, I.
2. "Neuroblastoma Workshop". Cancer therapy evaluation programme workshop/Cancer treatment. N.C.I., Bethesda, MD, USA. 14.1.1981.
3. Advanced course on immunological methods. FEBS Summer School. 24.5-6.6,1981. Budapest, Hungary.
4. XI Congreso Argentino de Pediatría. Mar del Plata, Argentina, 26.11.81.
5. Organiser and speaker "Immuno-oncologia pediatrica". CNR, Rome 26.2.83.
6. "Colloquium Protides of Biological Fluids". Brussels, Belgium 30.4.83.
7. "Colloquium Protides of Biological Fluids". Brussels, Belgium 1.5.84.
8. ASCO Meeting. Toronto 1984.
9. ASCO Meeting. Los Angeles 1986.
10. "Immunology International Meeting", Galloway, Ireland, 25.4.1986
11. EMBO practical course Advanced Flow Cytometry. Koln, Germany, 15-31.8.1988.
12. "Colloquium Protides of Biological Fluids". London, UK 20.4.1989.
13. Organiser and Speaker at 19th FEBS Satellite Meeting Workshop "Biochemistry of Neuroectodermal Tumours", 1st in Rome 1989.
14. Symposium "Neuroblastoma Research": Philadelphia (US), 1990.
15. "XXIst SIOOP Meeting". Rome 2-5. 10.1990.
16. Symposium "Neuroblastoma Research": Heidelberg (D), 1991.
17. Organiser and Speaker at 19th FEBS Satellite Meeting Workshop "Biochemistry of Neuroectodermal Tumours", 2nd in Rome 1993.

18. Organiser Conference "Liposomes as biomimetics". Rome 1993.
19. Director, Summer Course "Cell Differentiation and Death", International School of Biophysics "E. Majorana", Erice, in 1992.
20. Conference "Apoptosis in Cancer & AIDS" (by Montagnier & Tomei), Paris 2-5 .12.1993.
21. Director, Summer Course "Cell Differentiation and Death", International School of Biophysics "E. Majorana", Erice, in 1994.
22. VI Conference on Differentiation & Cancer (by Waxman), Hertzelia, Israel, 4-7.3.1994.
23. ECDO Euroconferences, European Cell Death Society, 2nd in Cork (IR), 1994.
24. Organiser and Speaker at 19th FEBS Satellite Meeting Workshop "Biochemistry of Neuroectodermal Tumours", 3rd in Rome in 1995.
25. FEBS Meeting, Basel, Switzerland 1995.
26. FASEB Meeting, Atlanta, Georgia 1995.
27. Organizer, Villa Vigoni/CDD Conference on Apoptosis. Como, Italy. June, 1995.
28. Chairman & Speaker, Cambridge Healththec Inst., Cell Death Conference, MIT, Cambridge, Mass 1995.
29. Organizer, Villa Vigoni/CDD Conference on Apoptosis. Como, Italy. May, 1996.
30. Organizer 4th Euroconference on Apoptosis, European Cell Death Organization, Capri, 1996 .
31. Organizer, GCI/ABCD course on Cell Death, L'Aquila, 1996.
32. Organizer, Villa Vigoni/CDD Conference on Apoptosis. Como, Italy. June, 1997.
33. Organizer, GCI/ABCD course on Cell Death, L'Aquila, 1997.
34. Keystone Symposium on Cell Death, Tamarron Colorado 21.3.1997.
35. Chairman & Speaker, Mechanisms of Cell Death, University of Tucuman, Argentina, 12-17.5.1997.
36. Organizer, Villa Vigoni/CDD Conference on Apoptosis. Como, Italy. June, 1997.
37. Gordon Research Conference on "Apoptosis", New Hampshire, 2.7.1997.
38. Eur Confer 'Calcium Signalling in the Cell Nucleus', Paraelios, 5.10.1997.
39. VII Conference Differentiation Therapy & Cancer (by Waxman), Paris 8.10.1997.
40. Mechanisms in toxicity: recent advances. European Science Foundation, Maratea, 10.10.1997.
41. Symposium "Neuroblastoma Research": Bath (UK), 1998.
42. Lorne Cancer Conference, Melbourne, Australia, 12-14.2.1998.
43. Organizer, Villa Vigoni/CDD Conference "NO & Redox Reactions". Como, Italy. April, 1998.
44. Organizer, Villa Vigoni/CDD Conference on Apoptosis. Como, Italy. May, 1998.
45. ECDO Euroconference, European Cell Death Society, 6th in Stockholm (S),1998.
46. Organizer, "Inherited Skin Diseases", Rome 12-14.5.1998.
47. Organizer, GCI/ABCD course on Cell Death, L'Aquila, 1998.
48. Organizer, S.I.B. course on "Protein structure & function", L'Aquila, 1998.
49. Chairman Cell Death Society (US), New York, 17-18.7.1998.
50. Seminar Series, Found. Promot. Cancer Res., National Cancer Center Hosp., Tokyo, Japan (Feb. 1999)
51. Organizer, Villa Vigoni/CDD Conference on Apoptosis. Como, Italy. May, 1999.
52. 7th EU/European Cell Death Society, Ein Gadi, Israel, 5-9 November 1999.
53. Society for Histochemistry, 41st Symposium, Gargellen, Austria, 22-25.9.1999.
54. ESF/EURESCO/EU Conference on Mechanisms in toxicity. San Feliu de Guixol, Spain. 7-12 April, 2000.
55. Organizer, Villa Vigoni/CDD Conference "NO & Redox Reactions". Como, Italy. April 12-15, 2000.
56. Organizer, Villa Vigoni/CDD Conference on Apoptosis. Como, Italy. June 1-4, 2000.
57. CDS 3rd Symposium on Apoptosis. El Escorial Monastery, Spain. May 6-10, 2000.
58. 6th Conference on Transglutaminase, Lyon, France 16-19 September, 2000.
59. Societa' Italiana Biochimica, Conference 2000, Napoli, Italy. September 20-23, 2000.
60. Organizer, 8th EU/European Cell Death Society, in Davos Switzerland, October 14-17, 2000.
61. 2000 Hanson Symposium, Adelaide, Australia 13-16 November, 2000.
62. Keystone Conference on Apoptosis, Keystone, Colorado, USA. 16-22 January 2001.
63. Organizer, Villa Vigoni/CDD Conference on Apoptosis. Como, Italy. May, 2001.
64. Medical Genetics Course, San Giovanni Rotondo, FG, Italy. June 14-16, 2001.
65. Organizer, FEBS course "Nerve Cells' Differentiation & Death". Spetses Island, Greece, Sept.15-24, 2001
66. European Cancer Conference Org. ,Lisbon, Portugal. October 21-25, 2001.
67. Organizer, Villa Vigoni/CDD Conference "NO & Redox Reactions". Como, Italy. April, 2002.
68. Organizer, 5th Int. Cell Death Society Conference, Australia, 1-4 June 2002.
69. Keynote Lecture, EuroCancer, 15th Conference, Paris 4-6 June 2002.
70. Organizer, Villa Vigoni/CDD Conference on Apoptosis. Como, Italy. June 26-30, 2002.
71. Organizer, 4th SASS Conference on "Apoptosis", Capri (I) 6-10 October 2002.
72. ESH-MD Anderson 3rd Conference on Apoptosis & Disease. Intra, Portugal 8-11 November 2002.
73. "Apoptosis 2003", Luxemburg, January 29-February 1, 2003.
74. Hermelin Brain Tumor Symposium on Apoptosis, Detroit, MI, April 4, 2003.
75. EMBO Workshop "Transgenesis and genome analysis", Brdo, Slovenia, April 8-13, 2003.
76. Transglutaminases in Biology & Medicine. Yamagata, Japan, 1-5 March 2003.
77. 7th Workshop Apoptosis in Bio-Medicine. Cosenza, Italy, 29-30 April 2003.
78. 5th Meeting Molecular Oncology, Positano, Italy, 12-15 May 2003.
79. Organizer, Villa Vigoni/CDD Conference on Apoptosis. Como, Italy. May 26-28, 2003.
80. Cancer from its birth to its death. Toscana, Italy,10-16 August 2003.
81. Signal transduction in cancer. Ettore Majorana School, Erice, Italy, 24-31 October 2003.
82. European Tissue Culture Society. Bristol, UK, 26-27 November 2003.
83. Keystone Conference on Apoptosis, Keystone, Colorado, USA. 3-8 February 2004.
84. Organizer, Villa Vigoni/CDD Conference on Apoptosis. Como, Italy. June 2-5, 2004.
85. 11th Advance Neuroblastoma Research. Genova, Italy. June 16-19, 2004.

86. 1st From Cage to Clinic-Non Human Primate research, Kunming, China, 27-30 October 2004.
87. p53 Workshop, Dunedin, New Zealand, 6-10 November 2004.
88. Congreso Conjunto Sociedades Biomedicas Mar del Plata, Argentina, 16-20 November 2004.
89. Claude Bernard Lecture, Societe' de Biologie, Paris, France, 25 November 2004.
90. p53 family in Genotoxicity, Rehovot, Israel, 2-4 December 2004.
91. Programmed Cell Death, Santiago del Chile, Chile. 13-16 April 2005.
92. Keystone Conference on Apoptosis, Keystone, Colorado, USA. 3-9 March 2005.
93. Organizer, Villa Vigoni/CDD Conference on Apoptosis. Como, Italy, May 29-31, 2005.
94. Cancer from its birth to its death. Toscana, Italy, 21-27 August 2005.
95. COMBIO, Biochemistry & Molecular Biology, Adelaide, Australia. 25-29 September 2005.
96. UK-China Governmental delegation Beijing, China, 20-25 October 2005.
97. Intern Symp Translational Res: Apoptosis & Cancer. Trivandrum, India. Dec 18-21, 2005
98. Journee Recherche "Apoptosis" CNRS/INSERM. Paris, France. June 21, 2005.
99. 6st SASS Conference. Molecular Targets in Cancer. Mallorca, Spain. October 13-15, 2005
100. 2nd GTCbio Tumor Progression & Chemo Resistance. Boston. September 18-20, 2005
101. Organizer, Death in the Alps. Innsbruck, Austria. January 23-26, 2006
102. "Arturo Leone Memorial" Salerno 12 May 2006.
103. Societa' Italiana Biochimica. Proteine. 2-4 June 2006.
104. Organizer, Cell Death Differentiation. Villa Vigoni, Como, Italy. June 25-28, 2006
105. Leukaemia and lymphoma Society Meeting. Toronto, Canada. July 11, 2006
106. DJ-1 Meeting. Toronto, Canada. July 13, 2006
107. From the cage to the bench. Primate Research. Kuming, China. August 13-16, 2006
108. 14th ECDO EuroConference on Apoptosis. Cagliari, ITA. 29 Sept-4 Oct, 2006.
109. "Apoptose et pathologies" Nantes, France. 18-20 Oct 2006.
110. Accademia Nazionale Lincei, "Proteins in Rome". 22 Nov 2006.
111. "EU Science: Collaboration Germany-Italy". Villa Vigoni. 31 Jan-2 Feb, 2007.
112. Academia Europea-The Klaus Tschira Foundation GmbH, "Cellular & molecular mechanism of tissue reparaire". Heidelberg, D. 1-3 march 2007.
113. Keynote Lecture. Winter School "Cell death, cancer & immunity" Obergurgl, Innsbruck, Austria. 7-9 March 2007.
114. Organizer. 3rd International p63/p73 workshop. Rome. 18-21 March 2006.
115. 4eme Symposium de Monastire "Toxiques Environnementaux". Tunisie. 20-24 March 2007.
116. Chair & speaker. GTC-bio's "Apoptosis in drug discovery". San Diego 22-23 March 2007.
117. Keynote Lecture. X Workshop "Apoptosis in Medicine". University Calabria. Cosenza 29-30 March 2007.
118. Connecting research with industry. Cranfield, UK 10-19 April 2007.
119. "Cell Biology Workshop" Sapienza University. 20 April 2007.
120. Signalling & metabolic pathways in cancer. Cantoblanco, Madrid, S. 11-13 June 2007.
121. Encyclopaedia Life Science. Wiley-Blackwell Publ. Richmond, UK. 23 June 2007.
122. Organizer. "Programmed Cell Death" Villa Vigoni. 23-27 June 2007.
123. "Cell cycle and death" University of Tehran, Iran. 26-28 June 2007.
124. "Genetics & treatment of Cancer" Siena, ITA. 18-25 August 2007.
125. Organizer. Nature Conference & CDD Conference "Cancer therapeutics: the road ahead" Capri, Italy. 8-10 October 2007.
127. Organizer. 6th International Symposium on Translational Research in Oncology. Dublin, Ireland. 11-14 October 2007.
126. Organizer. Nature Conference & CDD Conference "Discovery tools in cardiovascular disease" Capri, Italy. 14-16 /10/ 2007.
128. MRC Showcase in Oncology. Manchester, UK. 21-22 Nov 2007.
129. "Cell Death Symposium". The Rockefeller University, New York, US. 10 Dec 2007.
130. 24th Gene & Cancer Meeting. Warwick, UK. 11-13 Dec 2007.
131. Organizer. "3rd Luxemburg Conference on Apoptosis". Luxemburg 23-26 January 2008.
132. 1st Epistem "Skin biology" conference. Ghent, Belgium. 28-29 February 2008.
133. Winter School "Cell death, cancer & immunity" Obergurgl, Innsbruck, Austria. 26-29 March 2008.
134. Keynote Speech. Nobel Forum mini-symposium on Cell Death. 14 April, 2008.
135. Cell Death Mechanism Workshop. Bristol, UK. 23 April 2008.
136. Keynote Lecture. XXIX Cosmetic Medicine Congress. Rome, Italy. 16-18 May 2008.
137. Symposium "Targeting cell death pathways", Int Cell Death Soc/Chinese Biochem Soc. Shangai, China. 6-9 June 2008.
138. Organizer. "Programmed Cell Death" Villa Vigoni. 28-30 June 2008.
139. "Cell Stress and apoptosis" A Leone Workshop. Salerno, Italy. 3-4 July 2008.
140. "Cell Death" Gordon Conference. Il Ciocco, Lucca, Italy. 6-11 July 2008.
141. Summer School "Inflammation, Immunomodulation". Bern/Interlaken, Swiss. 10-11 August 2008.
142. 16th ECDO Eutorconference/5th Swiss Apoptosis Meeting. Bern 6-9 September 2008.
143. SIB/SBBM Society, Riccione, Italy. 24-26 September 2008.
144. Organizer. MRC-China Workshop on "Cell Death". Shanghai, China. 25 October 2008.
145. 14th International p53 Workshop. Shanghai, China. 27-31 october 2008.
146. Workshop "miR & Cancer". MRC/University of Leicester. December 10th, 2008.
147. Organizer, EMBO Workshop "Death in the Alps". Obergurgl (Innsbruck, Austria). 1-5 Feb 2009.
148. "Cancer Progression", Birmingham University, UK. 11 Feb 2009.
149. "DNA damage response". Ludwig Cancer Center, Oxford, UK 11 March 2009.
150. Organizer. "Neurodegeneration". CNR-NPG Conference. Rome, Italy. 18-20 May 2009.
151. "Tumour diagnosis and Therapy". Ischia, Italy. 20-23 May 2009.
152. Award "Feltrinelli Prize" for Biochemistry & Neuroscience by the President of Italy. Accademia Lincei, Rome 11 June 2009.
153. Organizer. Joint Rome University -Princeton's Institute Advanced Studies (NJ, US). 13-18 July 2009.

154. Organizer. "Cell Death Summer Course". Montalcino, Tuscany, Italy. 8-15 August 2009.
155. Organizer, "4th Workshop p63/p73 family". Toronto, Canada. 30/8/09 – 2/9/09.
156. ELS Meeting, Chicester, UK. 10-11 Septemebr 2009.
157. ECDO Meeting. Paris, France. 23-26 September 2009.
158. VIB Experimental Medicine Meeting. 22-23 October 2009.
159. Keynote Lecture. AICC "Apoptosis" Meeting. Florence, Italy. 2-4 December 2009.
160. Workshop "Death in the Alps". Obergurgl (Innsbruck, Austria). 6-9 Jan 2010.
161. Oak Foundation Review, University of Oxford, UK. 12 Jan 2010.
162. AACR Special Conference: Cell death mechanisms and cancer therapy. San Diego, CA, 1-4 Feb 2010.
163. Cell Death & Immunity Conference, Sao Paulo, Brasil. 8-11 Feb 2010.
164. German Society Cell Biology. Regensburg. 10-13 Mar 2010.
165. Ceinge Institute Workshop. Napoli 15-16 Mar 2010.
166. Chair. 2nd Sino-MRC conference on "Cell Death". Shanghai, China. 4-7 Apr 2010.
167. 1st Conference of the European Research Institute for Integrated Cellular Pathology (ERI-ICP) on "Integrated Cellular Pathology: Death, Danger & Degeneration", Institut Pasteur, Paris April 22-23, 2010.
168. Science Foundation Ireland. Dublin, IR. 3-4 May 2010.
169. Nobel Conference, 200th anniversary Karolinska, Nobel Forum. Stockholm, S. 23-27 May 2010.
170. Pharmacology Workshop, European Brain Res Inst, Cosenza. 3-4 Jun 2010.
171. Chair. Stem Cells at CNR. Rome. 1-2 Jul 2010
172. IARC, p53 isoforms, workshop. Lyon, France. 13-15 Sep 2010.
173. Antonini Prize. Italian Biochemical Society, Milan. 14-17 Sep 2010.
174. 6th Swiss Apoptosis Meeting. Bern, CH. 29-30 Sep 2010.
175. Italian Cancer Society. Rome. 3-6 Oct 2010.
176. 15th p53 workshop. Philadelphia, PA., USA. 8-12 Oct 2010.
177. Italian Pathology Society. Salerno. 14-17 Oct 2010.
178. Chair, Organizer. FEBS meeting on Cancer Metabolism. Capri, Italy. 23-26 Oct 2010.
179. Publishing Forum, Wiley-Blackwell. Oxford, UK. 1-2 Dec 2010.
180. Keynote Medal. Portuguese Biochemical Society. Porto, P. 15-17 Dec 2010.
181. Chair, Organizer. Cell Signalomics. Luxemburg. 26-29 Jan 2011.
182. Keynote. Indian Assoc Cancer Res. Kolkata, India. 6-9 Feb 2011.
183. Chair. EMBO Workhop "Death in the Alps". Obergurgl (Innsbruck, Austria). 10-14 Feb 2011.
184. Keynote. Shanghai Biology Conference. 23-26 Mar 2011.
185. In-Cosmetics Fair, Avant. Milan, I. 30 Mar 2011.
186. Chair. 2nd Sino-MRC conference on "Cell Death". Shanghai, China. 19-21 May 2011.
187. Mutant p53 workshop. Ariccia, Italy. 22-24 May 2011.
188. ICDS Meeting. Sao Paulo, Brasil. 10-13 Jun 2011.
189. Organizer. Stress Meeting. Salerno. 23-26 Jun 2011.
190. Organizer. FEBS Meeting. Turin, Italy. 25-30 Jun 2011.
191. ESDR skin biology course. Rome, I. 18-22 Jul 2011.
192. Summer course on Cell Death. Montalcino, Tuscany, I. 6-13 Aug 2011.
193. 1st Australian Cell Death Workshop. Lindemann Island, Aus. 21-15 Aug 2011.
194. DZNE Conference, Bonn, Germany. 1-4 Sep 2011.
195. Chair. 5th p63/p73 workshop. IARC, Lyon, France. 12-14 Sep 2011.
196. 19th ECDO Conference. Sockholm, Sweden. 14-17 Sep 2011.
197. "Cell Death" Cold Spring Harbor Laboratory Meeting, NY, USA. Oct 11-15, 2011.
198. 5th Barossa Meeting "Cell Signalling & Molecular Medicine", 23-26/11/2011 Adelaide, Australia.
199. Morgagni Medal. Morgagnane Lectures, 250th Anniversary. 7/12/2011 University Padua, Italy.
200. "Tumor Microenvironment", The Croucher Foundation; Advanced Study Institute. 9-13/1/2012 Hong Kong.
201. "Cell Death Model Organisms" EMBO Workshop. 19-23, 2012 Ein-Gedi, Israel.
202. "Ras-like GTPases & Tumor Suppressors" 26-29/2/2012 Tel Aviv University, Israel.
203. 63th Mosbacher Kolloquium, German Biochemical & Molecular Biology Society. 29-31/3/2012. Germany.
204. Chair. "Programmed Cell Death in Biology & Medicine" 4-5/6/2012 MSU Lomonosovsky, Moscow, Russia.
205. Chair. "Therapeutic Targets in Cell Death" 6-7/6/2012 St Petersburg State Institute Technology. Russia.
206. "Apoptosis & Cancer" 13-15/6/2012 Downing College, University Cambridge, UK.
207. "Cell Death" Gordon Conference. 15-20/7/2012 Il Ciocco, Lucca, Italy.
208. Chair. "Novel Therapeutic Strategies in Cancer" 12-13/9/2012 St Petersburg State Inst Technol. Russia.
209. Chair. 20th ECDO Conference. 14-17/9/2012 Rome, Italy.
210. "Molecular Mechanisms in Angiogenesis" FEBS Workshop. 14-17/10,2012. Capri, Italy.
211. 16th p53 Workshop. Sao Paulo, Brazil.
212. Keynote Speaker 25th AICC Meeting. 21-23/11/2012 Palermo.
213. Organizer, Chair. EMBO Workshop "Death in the Alps". Obergurgl (Innsbruck, Austria). 23-27 Jan 2013.
214. "Cell Processes: Life and death decisions". Biochemical Journal Symposium. Tsinghua University, Beijing. China 14/3/2013.
215. Chancellor's Award on Neuroscience. Louisiana State University. April 14, 2013.
216. 1st CDDIS & 4th Sino British Workshop on Cell Death. Shanghai, China. May 8-9, 2013.
217. Organizer, Chair. CDD-Retreat. Capri, Italy. June 9-11, 2013.
218. Organizer, Chair. "Proteosomal Degradation of Proteins". Saint Petersburg Institute Technology. Saint Petersburg, Russia. 11-6-2013.
219. 6th International Mutant p53 Workshop. Toronto, Canada June 15-18, 2013.

220. 25th Pezcoller Symposium. "Metabolism and Tumorigenesis". Trento, Italy. June 20-22, 2013.
221. Organizer, Chair. "Therapeutic Targets for Cell Death in Cancer", Pharmacy Summer School" Rome, Italy. June 24 – July 5, 2013
222. Organizer, Chair. "Cell Death in Disease". Saint Petersburg Institute Technology. Saint Petersburg, Russia. July 8th, 2013
223. 8th Tuscany Retreat on Cancer Research and Apoptosis. "Genetic profiling, resistance mechanism and novel treatment concepts in cancer". Sarteano, Siena. August 3-10, 2013.
224. Organizer, Chair. 6th p63/p73 International Workshop. Kazusa Akademia Park in Chiba, Japan. September 15-18, 2013.
225. 21st ECDO EuroConference on Cell Death. Paris, France. September 25-28th, 2013.
226. COMBIO 2013. Perth, Australia. September 29-October 3, 2013.
227. Organizer, Chair. Advanced Course on "Cancer Therapeutics". Saint Petersburg Institute Technology. Saint Petersburg, Russia. 11-October-2013.
228. "EEC-ectodermal dysplasia and syndromes". Padova, Italy November 22-23, 2013.
229. "Molecular mechanisms of cancer". C.N.R. Napoli, Italy November 28-29, 2013.
230. Ageing Workshop "Aviesan". Paris, France. December 2-3, 2013.
231. 31st CARD, Congres Annuel Recherche Dermatologique. Paris, France. December 10-11, 2013.
232. 2nd EACR Special Conference: Cell Death in Cancer. Amsterdam, Netherland. 30/1-1/2, 2014.
233. Expert Panel, Cancer Research-UK, London 4-5 March 2014.
234. Keynote Lecture. Winter School "Cell death & cancer" Obergurgl, Innsbruck, Austria. 6-9/3/2014.
235. Biochemical Journal Workshop. London 20-21 March 2014.
236. "Challenges and Solutions in Cancer Research and Treatment" Angra dos Reis, Brasil, April 27-30, 2014.
237. Organizer, Chair. CDD-Retreat. Capri, Italy. May 19-21, 2013.
238. Workshop on Tumour Immunology. Toronto. June 5th, 2014.
239. FEBS Publication Committee, Budapest, Hungary. 6-7 June 2014.
240. Gordon Research Conference on "Cell Death". Mount Snow Resort, Vermont. June 8-12, 2014.
241. International p53 Workshop. Stockholm, Sweden, 15-19 June 2014.
242. 13th International Summer School on "Inflammation, Immunomodulation, Inspiration". Bern, Swiss, July 27-29, 2014
243. Keynote Lecture. National Congress of Biochemistry and Molecular Biology, Xiamen, China, 21-23 August 2014.
244. "Pancreatic Cancer", Ravello, Italy. 30 August 2014.
245. Ministry of Education Megagrant Meeting. Saint Petersburg, Russia, 17-20 September 2014.
246. 22nd ECDO EuroConference on Cell Death. Crete, Grece. October 1-4, 2014.
247. 3rd CDDIS & 6th Sino British Workshop on Cell Death. Shanghai, China. October 13-15, 2014.
248. Keystone Symposium on "Cell Death Signaling in Cancer and the Immune System". Guaruja, São Paulo, Brasil. October 28-November 2, 2014.
249. IT2014 Chronic Inflammation in Cancer. Havana, Cuba. November 10-14, 2014.
250. "Cancer beyond oncogenes" Symposium Honolulu, Hawaii, USA. 16-20 January 2015.
251. 2nd International Conference on Frontiers in Biological Sciences. Rourkela, Odisha, India. 22-24 January 2015.
252. "From zero to DRG60" Symposium. Mount Sinai, New York 14-16 February, 2015.
253. "Protein Degradation mini-workshop. University Rome Tor Vergata. 21 February, 2015.
254. "Cervello in fuga" two days outreach music events. Alexander Platz, Rome. 27-28 February, 2015.
255. "Etica della Ricerca Scientifica" conference. Accademia Lincei, Rome. 24 March, 2015.
256. SPORE Consortium meeting on Mesothelioma in Reno, NV, USA. 26-28 March, 2015.
257. "4th Cell Cycle & Cancer" conference. Marseille, France. 7-10 April, 2015.
258. "L'etica nella ricerca biomedica". Rome, Italy. 9 April, 2015.
259. 31st Annual 'Genes & Cancer' Meeting, Cambridge, UK. 13-15 April, 2015.
260. "New Frontiers in Oncology" workshop. Rome Tor Vergata, Italy. 27 April, 2015.
261. 2015 Capri CDD-Retreat. Capri, Italy. 17-20 May, 2015.
262. "Cell Death & Differentiation" workshop. Rome Tor Vergata. 20 May, 2015.
263. "Stratified Medicine" workshop. Bern University, Switzerland. 3 June, 2015.
264. "Current Biology Advances" Novosibirsk, Siberia, Russia. 12-14 July, 2015.
265. "Genetic profiling, mechanism and novel treatment concepts in cancer". Montalcino, Italy 1-8 August, 2015.
266. "Bridging the cancer research world" Symposium Honolulu, Hawaii, USA. 20 August 2015.
267. "p53 isoforms" workshop. Aix-en-Provence, France. 21-23 September, 2015.
268. "Molecular and cellular biology for cancer therapy". Saint Petersburg, Russia. 22-25 October, 2015.
269. "Cell Death, Inflammation & Cancer". Saint Petersburg, Russia. 29-30 October, 2015.
270. 7th "Frontiers in Cancer Science" Singapore. 2-4 November, 2015.
271. "The 6th Cell Death & Disease Symposium on Stem Cells, Cancer and Microenvironment". Changzhou and Soochow, China. 7-8 November, 2015.
272. "New insights into cell death and cancer signalling". Tel Aviv, Israel. 14-15 November, 2015.
273. "7th Barossa Meeting". Adelaide, Australia. 18-21 November, 2015.
274. "Bcl2 family in cancer biology" workshop. Obergurgl, Austria. 2-6, February 2016
275. Chair. "Remembering Sergio Chimenti" Dermatology Workshop. Rome April, 1. 2016
276. 10th EWCD "Death never dies" Fiuggi, Italy 3-8th April 2016.
277. Chair. 7th International p63/p73 workshop. Harvard. Boston MA, USA April 22-24, 2016.
278. Chair. CDD-retreat. Capri, Italy 1-3rd, May, 2016.
279. Chair. Cell Death Workshop. Rome, Italy 4th, May, 2016.
280. Keynote Lecture. ItPA Proteomic Association. Perugia, May 16th-19th 2016.
281. FEBS Publishing Committee. Capri, Italy. May 28th 2016.
282. 4th International Conference on Tumour Microenvironment and Cellular Stress: Signalling, Metabolism, Imaging and Therapeutic Targets. Rhodes, Greece, from June 5-10, 2016.

283. Nobel Conference "The Cell Cycle and Cell Death in Disease". Nobel Forum, Karolinska, Stockholm, Sweden. June 8-11, 2016.
284. "Cell Death in Neurodegeneration and Cancer". Villa Vigoni, Como, Italy. June 22-25, 2016.
285. Gordon Conference "Cell Death". Gerona, Spain. 3-8 July 2016.
286. "Systems biology of cell death", BGRS\SB – 2016, Novosibirsk, Siberia, Russia. August 28-31 2016.
287. 9th SWISS Apoptosis Meeting. Bern. Bern, September 8–9, 2016.
288. "Science of the Future" Megagrant in 2016. Kazan, Russia. 20-23 September 2016.
289. 14th FISV Congress. Rome 20-24th September, 2016.
290. Russian Academy of Sciences. XX Mendeleev Congress on General and Applied Chemistry. Ekaterinburg, 26-30 September 2016.
291. 7th international symposium on DNA Damage Response & Human Disease (icBEST/isDDRHD-2016), October 14-17, 2016 in Chengdu, China.
292. Chair. CDDisease Meeting. October 18-21st, 2016. Changzhou, China.
293. 7th International Mutant p53 Workshop will be taking place in Melbourne, October 26-28, 2016.
294. 4th International Bio-Medical Scientific Cyprus Congress. School of Medicine, European University Cyprus. November 4 - 5, 2016.
295. 1st Research Group Leader Symposium. Deutsches Zentrum für Neurodegenerative Erkrankungen. Bonn, Germany. 8-9 November, 2016.
296. 29th Annual Conference of Italian Association of Cell Cultures on "Molecular Biotechnology". L'Aquila, Italy, 23-25 November 2016.
297. Chair, "Genes versus Environment in cancer". University Rome Tor Vergata, Italy. December 2, 2016.
298. Invited Guest, Nobel Ceremony. Stockholm, Sweden. December 7-10, 2016.
299. "Cell Death, Inflammation & Cancer" EMBO workshop. Obergurgl, Austria. 10-14, January 2017
300. 8th Weinman Symposium "Gene X Environment Interaction" Conference. Honolulu, Hawaii, USA. 6-27 January 2017.
301. "Cell Death in Toxicology: A Tribute to Sten Orrenius". Stockholm, Sweden. 14 February 2017.
302. ZOMES-IX, protein ubiquitylation. Rome, Italy. 15-17 February 2017.
303. 1st Fusion Conference 'Cell Death, Cell Stress and Metabolism: From Basic Mechanisms to Novel Treatment Options', Cancun, Mexico from 14th – 17th March, 2017.
304. Academia Medica Romana. Award Conference. May 4th, 2017.
305. I WORKSHOP: "Molecular mechanisms of autophagy and their application to diseases". Federal University of São Paulo, UNIFESP. 1-2 June, 2017.
306. 63rd Meeting Italian Embryology Group. Rome 12-15 June, 2017.
307. 3rd International p53 Isoforms Conference. 18th - 21st June 2017 Where: Bergen, Norway.
308. Chair. CDD-retreat. Capri, Italy. 27-30 June, 2017.
309. 17th International p53 Workshop. Singapore. 8-13 July, 2017.
310. EPI-1, novel drugs, chromatin modulation from basic research to disease. Rome. 15 September, 2017.
311. 5th International Bio-Medical Scientific Cyprus Congress. School of Medicine, European University Cyprus. Nov 1-3, 2017.
312. 9th Weinman Symposium "Gene Metabolism & Cancer" Conference. Honolulu, Hawaii, USA. 30 November – 1 /12/ 2017.
313. Chair. CDDisease Meeting. November 4-6th, 2017. Changzhou, China.
314. Dean's Award Lecture in Medicine & Neuroscience. Louisiana State University, USA. 20/04/2018.
315. Scientific Integrity. Science Festival. Bologna, Italy. 03/05/2018.
316. "A call for action to improve reproducibility" Accademia Lincei, Rome, Italy 22/05/2018.
317. Chair. CDD-retreat. Capri, Italy. 30 May-2 June, 2018.
318. 2018 Korean Conference of Brain and Neuronal Science, August 30-31, 2018, in Seoul, Korea.
319. 2nd Frankfurt Conference on Quality Control in Life Processes & 8th p63/p73 Workshop. Germany. 2-6/09/2018.
320. 10th Swiss Apoptosis Meeting Bern, Swiss. 12-14/09/2018.
321. Chair. 9th CDD conference on "Genes vs Environment in Cancer". Cambridge, UK. 17-19/09/2018.
322. DermArt. Rome, Italy. 21-22/09/2018.
323. 26th ECDO conference, St. Petersburg, Russia. 10-12/10/2018.
324. New Trends in Low Vision & Neuroprotection. Keynote speaker. Cosenza, Italy. 8-9/11/2018.
325. 190th Anniversary St Petersburg Institute of Technology, chaired by Dmitri Medvedev. 28/11/2018.
326. Nobel Assembly Celebrations. Stockholm, Sweden. 10/12/2018.
327. Publish or Perish and scientific integrity. Lucca, Italy. 17/12/2018.

SELECTED PUBLICATIONS

100. Melino G, Bernassola F, Knight R, Nistico G, Finazzi Agro A. S-nitrosylation regulates apoptosis. **Nature**. 1997. 388:432-3.
113. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, Levrero M, Melino G. Two new p73 splice variants, gamma and delta, with different transcriptional activity. **J Exp Med**. 1998. 188: 1763-1768.
118. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG, Levrero M, Wang JYJ. Regulation of the p53 homolog p73 by c-Abl tyrosine kinase in cell death response to cisplatin. **Nature**. 1999. 399: 806-809.
146. De Laurenzi V, Melino G. The little devil of death. **Nature**. 2000. 406: 135-136.
155. Melino G. The Syren's song (Concept: apoptosis). **Nature**. 2001. 412:23.
173. Melino G, De Laurenzi V, Vousden KH p73 and cancer. **Nature Review Cancer**. 2002. 2: 605-615
185. Melino G. A thirst for knowledge: Gerry Melino. (lifelines) **Nature**. 2003. 421: 697.

185. Szondy Z, Piacentini M, Aeschliman D, Kovacs J, Kiss I, Birckbichler P, *Melino G*, Fésüs L. TG2^{-/-} mice reveal a phagocytosis-associated crosstalk between macrophages and apoptosis. **PNAS-USA**. 2003. 100:7812-7.
199. Aqueilan E, Pekarsky Y, Herrero J, Palamarchuk A, Letofsky J, Trapasso F, Han S, *Melino G*, Croce CM. Functional association between Wwox tumour suppressor protein and p73, a p53 homolog. **PNAS-USA**. 2004. 101,13:4401-4406.
200. *Melino G*, Lu X, Gasco M, Crook T, Knight R. Functional regulation of p63/p73. **TIBS**. 2003. 28,12:663-70.
211. Bernassola F, Salomoni P, Oberst A, Di Como CJ, Pagano M, *Melino G*, Pandolfi PP. Ubiquitin-dependent degradation of p73 is inhibited by PML. **J Exp Med**. 2004. 199 (11): 1545-57.
216. Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu Y-C, Vousden KH, Cesareni G, *Melino G*. The ubiquitin-protein ligase Itch regulates p73 stability. **EMBO Journal**. 2005. 24 (4): 836-848.
217. Candi E, Schmidt R, *Melino G*. Cornified envelope: skin cell death model. **Nature Rev Mol Cell Biol**. 2005. 6:328-40.
220. Gressner O, Schilling T, Candi E, Oren M, *Melino G*, Krammer PH, Stremmel W, Mueller M. TAp63 induces apoptosis by activating signaling via death receptors and mitochondria. **EMBO J**. 2005. 24(13):2458-71.
242. Viganó M, Lamartine J, Testoni B, Merico D, Alotto D, Castagnola C, Robert A, Candi E, *Melino G*, Gidrol X, Mantovani R. New p63 targets in keratinocytes identified by genome-wide approach. **EMBO J**. 2006. 25,21:5105-16.
243. Rossi M, Aqueilan R, Neale M, Candi E, Salomoni P, Knight RA, Croce CM, *Melino G*. The E3 ubiquitin ligase ITCH controls the protein stability of p63. **PNAS-USA**. 2006. 103, 34: 12753-58.
244. Barcaroli D, Dinsdale D, Neale MH, Buongiorno-Borbone L, Sayan AE, McWilliam J, Smith TM, Fava E, Knight RA, *Melino G*, De Laurenzi V. FLASH is an essential component of the Cajal bodies. **PNAS-USA**. 2006. 103,40:14802-7.
245. Barcaroli D, Buongiorno-Borbone L, Terrinoni A, Hofmann T, Rossi M, Knight RA, Matera AG, *Melino G*, De Laurenzi V. FLASH is required for histone transcription and S-phase progression. **PNAS-USA**. 2006. 103, 40: 14808-12.
262. Candi E, Rufini A, Terrinoni A, Giamboi-Miraglia A, Lena AM, Mantovani R, Knight RA, *Melino G*. ΔNp63 regulates thymic development through enhanced expression of FgfR2 and Jag2. **PNAS-USA**. 2007. 104,29: 11999-12004.
263. Sayan BS, Sayan AE, Yang AL, Aqueilan RI, Candi E, Cohen GM, Knight RA, Croce CM, *Melino G*. Cleavage of the transcription-inhibitory domain of p63 by caspases enhances apoptosis. **PNAS-USA**. 2007. 104,26: 10871-76.
264. Oberst A, Malatesta M, Murillas R, Sharma P, Kuehn MR, Oren M, Croce CM, Bernassola F, *Melino G*. The Nedd4 Binding Partner 1 (N4BP1) protein is an inhibitor of the E3 ligase Itch. **PNAS-USA**. 2007. 104, 27: 11280-11285.
282. Bernassola F, Karin M, Ciechanover A, *Melino G*. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. **Cancer Cell**. 2008. 14 10-21.
283. Tomasini R, Tsuchihara K, Wilhelm M, Rufini A, Kaplan D, *Melino G*, Jurisicova A, Mak TW. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. **Genes & Development**. 2008. 22, 19: 2677-91.
284. M Sundvall, A Korhonen, I Patero, E Gaudio, *G Melino*, CM Croce, R Aqueilan, K Elenius. Isoform-specific monoubiquitination, endocytosis, degradation of alternatively spliced ErbB4 isoforms. **PNAS-USA**. 105(11):4162-7.
285. Tomasini R, Mak TW, *Melino G*. The p53 family, aneuploidy and cancer. **Trends Cell Biology**. 2008. 18,5: 244-252.
286. Aberdam D, Candi E, *Melino G*. miRNAs, "stemness" and skin. **Trends in Biochemical Sciences**. 2008. 33: 583-91.
305. Tomasini R, Tsuchihara K, Tsuda C, Lau SK, Wilhelm M, Rufini A, Tsao MS, ..., *Melino G*, Mak TW. TAp73 regulates the Spindle Assembly Checkpoint by modulating BubR1 activity. **PNAS-USA**. 2009. 106(3): 797-802.
318. Gonfloni S, Di Tella L, Caldarola S, Mattei M, Candi E, De Felici M, *Melino G*, Cesareni G. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. **Nature Medicine**. 2009. 15(10):1179-85.
331. Dulloo I, Gopalan G, *Melino G*, Sabapathy S. The ΔNp73 oncogene is degraded in a c-Jun-dependent manner upon genotoxic stress through the antizyme-mediated pathway. **PNAS-USA**. 2010. 107(11):4902-7.
341. Wilhelm MT, Rufini A, Wetzel MK, Tsuchihara K, Inoue S, Tomasini R, Itie-Youten A, Wakeham A, Arsenian-Henriksson M, *Melino G*, Kaplan DR, Miller FD, Mak TW. Isoform-specific p73 knockout mice reveal a novel role for ΔNp73 in the DNA damage response pathway. **Genes & Development**. 2010; 24(6):549-60.
346. Sayan BS, Agostini M, Chen A-L, Tucci P, Bernardini S, Knight RA, *Melino G*. Differential control of TAp73 and ΔNp73 protein stability by the ring finger ubiquitin ligase PIR2. **PNAS-USA**. 2010. 107(29): 12877-82.
349. *Melino G*. A cancer biologist weighs up p53, metabolism and cancer (Journal Club). **Nature**. 2010. 466: 905.
359. Levine AJ, Tomasini R, McKeon FD, Tak Mak W, *Melino G*. The p53 family: guardians of maternal reproduction. **Nature Review Mol Cell Biol**. 2011. 12(4): 259-65.
360. Boase NA, et al. Respiratory distress and lethality in Nedd4-2-deficient mice. **Nature Communications**. 2011;2:287.

365. Notari M, Hu Y, Koch S, Lu M, ..., Candi E, Melino G, Lu X. Inhibitor of apoptosis-stimulating protein of p53 (iASPP) prevents senescence and is required for epithelial stratification. **PNAS-USA**. 2011 Oct 4;108(40):16645-50.
368. Agostini M, Tucci P, Killick R,, McKeon F, Knight RA, Mak TW, Melino G. Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. **PNAS-USA**. 2011 Dec 27;108(52):21093-8.
369. Agostini M, Tucci P, ..., Ventura A, Concepcion CP, Han YC, Candi E, Knight RA, Mak TW, Melino G. microRNA-34a regulates neurite outgrowth, spinal morphology, and function. **PNAS-USA**. 2011 Dec 27;108(52):21099-104.
372. Rivetti di Val Cervo P, Lena A, Nicoloso M, Rossi S, Mancini M, Zhou H, Saintigny G, Dellambra E, Calin GA, Candi E, *Melino G*. p63-microRNA feedback in keratinocyte senescence. **PNAS-USA**. 2012; 109(4):1133-8.
401. Amelio I, Lena AM, Viticchiè G, Shalom-Feuerstein R, Terrinoni A, Dinsdale D, Russo GD, Fortunato C, Bonanno E, Spagnoli LG, Aberdam D, Knight RA, Candi E and *Melino G*. A microRNA triggers epidermal differentiation by controlling actin cable dynamics, intercellular adhesion and cell migration. **J Cell Biol**. 2012. 199,2: 347-363.
402. Tucci P, Agostini M, Crespi F, Vousden K, Lowe S, Levine A, Knight, *Melino G*. Loss of p63 and its miR-205 target results in enhanced cell migration and metastasis in prostate cancer. **PNAS-USA**. 2012; 109:15312-7.
405. Rufini A, Niklison MV, Inoue S, Tomasini R, Harris I, Federici M, Dinsdale D, Knight RA, *Melino G* [*corresp*], Mak TW. TAp73 depletion accelerates aging through metabolic dysregulation. **Genes & Development**. 2012. 26:2009-14.
425. Terrinoni A, et al. Role of p63 and the Notch pathway in cochlea development and sensorineural deafness. **PNAS-USA**. 2013. 110(18):7300-5.
434. Rotblat B, et al. HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response. **PNAS-USA**. 2014. 111(8):3032-7
450. Inoue S, et al. TAp73 is required for spermatogenesis and the maintenance of male fertility. **PNAS-USA**. 2014. 111(5):1843-8.
475. Amelio I, et al. TAp73 opposes tumor angiogenesis by promoting hypoxia-inducible factor 1 α degradation. **PNAS-USA**. 2015; 112(1):226-31.
476. Memmi EM, et al. p63 sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signalling. **PNAS-USA**. 2015; 112(11):3499-504.
477. Viticchiè G, et al. p63 supports aerobic respiration through hexokinase II. **PNAS-USA**. 2015; 112:11577-82.
478. Amelio I, Melino G. The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression. **Trends Biochem Sci**. 2015 Aug;40(8):425-34.
479. Melino G, et al. Maintaining epithelial stemness with p63. **Science Signalling**. 2015 Jul 28;8(387):re9.
509. Inoue S, et al. Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. **Cancer Cell**. 2016; 30(2):337-48.
558. Compagnone M, et al. Δ Np63-mediated regulation of hyaluronic acid metabolism and signaling supports HNSCC tumorigenesis. **PNAS-USA**. 2017;114(50):13254-13259. doi: 10.1073/pnas.1711777114.
559. Niklison-Chirou MV, Erngren I, ..., Melino G, Marino S. TAp73 is a marker of glutamine addiction in medulloblastoma. **Genes Dev**. 2017 Sep 1;31(17):1738-1753. doi: 10.1101/gad.302349.117.
560. Melino G. Order must spring from chaos in Italian research. **Nature**. 2018 Apr;556(7702):436.
561. Di Rita A, et al. HUWE1 E3 ligase promotes PINK1/PARKIN-independent mitophagy by regulating AMBRA1 activation via IKK α . **Nature Commun**. 2018 Sep 14;9(1):3755. doi: 10.1038/s41467-018-05722-3.
562. Pieracciolli M, et al. ZNF281 inhibits neuronal differentiation and is a prognostic marker for neuroblastoma. **PNAS-USA**. 2018 Jul 10;115(28):7356-7361. doi: 10.1073/pnas.1801435115.
563. Marini A, et al. TAp73 contributes to the oxidative stress response by regulating protein synthesis. **PNAS-USA**. 2018 Jun 12;115(24):6219-6224. doi: 10.1073/pnas.1718531115.
564. Amelio I, et al. p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. **PNAS-USA**. 2018 Nov 13;115(46):E10869-E10878.
565. Sanarico AG, et al. The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia. **Leukemia**. 2018 Apr;32(4):911-919. doi: 10.1038/leu.2017.342. PMID: 29209041
568. Bufalieri F, et al. ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of β TrCP. **Nature Commun**. 2019; 10(1):3304. doi: 10.1038/s41467-019-11093-0.
580. Bernassola F, Chillemi G, Melino G. HECT-Type E3 Ubiquitin Ligases in Cancer. **Trends Biochem Sci**. 2019. pii: S0968-0004(19)30180-X. doi: 10.1016/j.tibs.2019.08.004.
596. Amelio I, Panatta E, Niklison-Chirou MV, Steinert JR, Agostini M, Morone N, Knight RA, Melino G. The C terminus of p73 is essential for hippocampal development. **PNAS-USA**. 2020 Jul 7;117(27):15694-15701. doi: 10.1073/pnas.2000917117. PMID: 32571922
601. Liu K, Lin L, Li Q, Xue Y, Zheng F, Wang G, Du L, Hu M, Huang Y, Shao C, Kong X, Melino G, Shi Y, Wang Y. Scd1 controls de novo beige fat biogenesis through succinate-dependent regulation of mitochondrial complex II. **PNAS-USA**. 2020 Feb 4;117(5):2462-2472. doi: 10.1073/pnas.1914553117. PMID: 31953260
621. Lena AM, et al. The p63 C-terminus is essential for murine oocyte integrity. **Nature Commun**. 2021;12(1):383.